Breast tumors that were negative for estrogen receptor, progesterone receptor and HER2 gene amplification, otherwise known as “triple negative” breast cancers also strongly expressed CT-X antigens [28], [29] compared to receptor-positive tumors. This evidence concerns the gene CYP27A1 and breast neoplasm.